The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global pen needles market reached a value of US$2.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$6.5 Billion by 2027, exhibiting at a CAGR of 15.01% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Pen needles are disposable hollow needles used in pen injectors for delivering pharmaceutical drugs in the subcutaneous tissues of the body. The needle is fixed in the plastic hub of the medical injector pen and consists of plastic caps and individual wrapping for enhanced security and sterilization. Pen needles are manufactured using electro-polishing techniques to achieve smooth, fine and thin point tips for convenient penetration. They are available in a wide variety of gauge sizes and lengths and are majorly used by diabetic patients that require multiple dosages of insulin injections every day. In comparison to the traditionally used syringes and vials, pen needles are highly cost-effective, convenient to use, portable and do not require refrigeration.
The increasing prevalence of diabetes mellitus (DM) and other chronic medical disorders, such as osteoporosis, cardiovascular disease (CVD) and multiple sclerosis, is one of the key factors driving the growth of the market. The treatment of these ailments require multidrug regimen that involves daily or weekly administration of medicinal drugs with injector pens. Moreover, the rising geriatric population, which is more susceptible to chronic ailments is contributing to the growth of the market. Insulin pens provide a reliable, accurate and simplified dosing solution to the elderly patients and facilitate self-administration. Additionally, various product innovations, such as the development of ultra-thin and short-length needles with improved drug delivery systems, are acting as other growth-inducing factors. The traditionally used needles were difficult to use during self-dosage and caused more pain and discomfort to the patients. Other factors, including the increasing healthcare expenditure capacities of the masses, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pen needles market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, needle length, therapy, mode of purchase and end user.
Breakup by Type:
Breakup by Needle Length:
Breakup by Therapy:
Breakup by Mode of Purchase:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare) and Ultimed Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Type, Needle Length, Therapy, Mode of Purchase, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare) and Ultimed Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global pen needles market was valued at US$ 2.8 Billion in 2021.
We expect the global pen needles market to exhibit a CAGR of 15.01% during 2022-2027.
The rising prevalence of chronic disorders, such as Diabetes Mellitus (DM), that require daily or
weekly administration of medicinal drugs, is primarily driving the global pen needles market.
The sudden outbreak of the COVID-19 pandemic has led to rising utilization of pen needles for self-
administration of drugs, particularly among patients suffering from medical ailments, to avoid
coronavirus infection upon hospital or clinic visits.
Based on the type, the global pen needles market can be segregated into standard pen needles and
safety pen needles. Currently, standard pen needles account for the largest market share.
Based on the needle length, the global pen needles market has been divided into 4mm, 5mm, 6mm,
8mm, 10mm, and 12mm. Among these, 8mm long needles currently exhibit a clear dominance in the
Based on the therapy, the global pen needles market can be bifurcated into insulin, GLP-1, and
growth hormones, where insulin therapy holds the majority of the total market share.
Based on the mode of purchase, the global pen needles market has been categorized into retail and
non-retail. Currently, retail purchase exhibits a clear dominance in the market.
Based on the end user, the global pen needles market can be segmented into hospitals and clinics,
home healthcare, and others. Among these, hospitals and clinics currently represent the largest
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin
America, and Middle East and Africa, where Europe currently dominates the global market.
Some of the major players in the global pen needles market include A. Menarini Diagnostics srl,
Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan
Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple
Diagnostics, Trividia Health Inc. (Sinocare), and Ultimed Inc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at